## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38005-0188

Applicant:

1

Gerhard JAEHNE et al.

Confirmation No. Not Yet Assigned

Appl. No.:

Not Yet Assigned

Examiner: Vollano, J.F. (parent case)

Divisional of 10/230,353

Filing Date:

October 22, 2003

Art Unit: 1621 (parent case)

Title:

POLYSUBSTITUTED INDAN-1-OL SYSTEMS FOR THE PROPHYLAXIS

OR TREATMENT OF OBESITY

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA. 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action, which would be appropriate to antedate or otherwise remove as a competent reference any document, which is determined to be a *prima* facie prior art reference against the claims of the present application.

## RELEVANCE STATEMENT

Applicants are submitting herewith on Form PTO/SB/08A, a listing of the documents cited by, or submitted to the Patent Office in parent application Serial No. 10/230,353, filed

Divisional Application of U.S. Application Serial No. 10/230,353, filed August 29, 2002

Attorney Docket No.: 38005-0188

August 29, 2002. The relevance of these prior art documents is explained in the parent

application. As provided in 37 C.F.R. § 1.98(d), copies of the documents are not being provided

since they were previously cited by or submitted to the Patent Office in parent application Serial

No. 10/230,353.

**TIMING/FEE** 

The instant Information Disclosure Statement is being filed in compliance with 37 C.F.R.

§1.97(b) within three months from the filing date of the above-identified application, therefore,

no fee is required in connection with its filing.

Applicants respectfully request that the listed documents be considered by the Examiner

and be made of record in the present application and that an initialed copy of Form PTO/SB/08A

be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: October 27, 2003

HELLER EHRMAN WHITE &

MCAULIFFE

1666 K Street, N.W., Suite 300

Washington, DC 20006

Telephone:

(202)

Facsimile:

(202) 912-2020

Customer No. 26633

Patricia D. Granados Attorney for Applicant

Registration No. 33,683

38005-0184

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known To Be Assigned (divisional application of U.S. Application Number Patent Application Serial No. 10/230,379) INFORMATION DISCLOSURE October 27, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Gerhard JAEHNE et al. Group Art Unit 1621 (parent case) (use as many sheets as necessary) J.F. Vollano (parent case) **Examiner Name** 

Attorney Docket Number

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant			
Initials *	No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear			
-		US-						
		US-						
		US-						

Sheet

Of 2

		FOREIGN PA	TENT DOCU	MENTS		
		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Applicant of Cited  Document	Where Relevant Passages or Relevant Figures Appear	Т <sup>6</sup>
	1	EP 0009554	04-06-1980	Schering AG		
	2	WO 97 20806 A	06-12-1997	Venantius Limited		
	3	WO 97/26265	07-24-1997	Novo Nordisk A/S		
	4	WO 97/41097	11-06-1997	Dr. Reddy's Research Foundation		
	5	WO 99/08871	03-05-1998	Novo Nordisk A/S		

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
	1	D. Edwards et al., "The Oxidation of Alkyl Sulphides". J. Chemical Society, 1954, pp 3272-3284					
	2	Ford, J.F., et al., "Stereochemistry of the Co-oxidation Products of Indene and Thiophenol." <i>Tetrahedron</i> , Vol. 4, 1958, pp. 325-336.					
	3	Lambert, P.D., et al., "Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity." <i>PNAS</i> , Vol. 98, No. 8, April 10, 2001, pp. 4652-4657.					
	4	Maiti, A.K., et al., "Polyethylene Glycol (PEG) 4000 Catalysed Regioselective Nucleophilic Ring Opening of Oxiranes - A New and Convenient Synthesis ofβ-Hydroxy Sulfide." <i>Tetrahedron</i> , Vol. 50, No. 35, pp. 10483-10490.					
	5	Monteiro, Hugo J., et al., "A New Synthesis of β-Keto-Phenylsulfoxides." <i>Tetrahedron Letters,</i> No. 11, 1975, pp. 921-924.					
	6	A. V. SVIRIDOVA et al., A Method for the Selective Oxidation, Translated from <i>Zhurnal Organicheskoi Khimii</i> ,, Vol. 7, No. 12, pp. 2480-2483, December, 1971, original Article submitted December 21, 1970 (translated pages include 2577-2580)					

Signature Considered
----------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional) . <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.
<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449A/PTC	)			C mplete if Known
11156		DIC	OL OSLIDE	Application Number	To Be Assigned (divisional application of U.S. Patent Application Serial No. 10/230,379)
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 27, 2003
				First Named Inventor	Gerhard JAEHNE et al.
				Group Art Unit	1621 (parent case)
(use as many sheets as necessary)			necessary)	Examiner Name	J.F. Vollano (parent case)
Sheet	2	Of	2	Attorney Docket Number	38005-0184

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant			
Initials *	No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear			
		US-						
		US-						
		US-						

		FOREIGN PA	TENT DOCU	MENTS		
	<u> </u>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )		Applicant of Cited Document		T <sup>6</sup>
	6	WO 99/03861	01-28-1999	Novo Nordisk A/S		-
	7	WO 01/12176	02-22-2001	Sanofi-Synthelabo		
	8	WO 01 62746 A1	08-30-2001	Aventis Pharma Deutschland GmbH		
	9	WO 01 02373 A	01-11-2002	Merck Patent GmbH		
	10					

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
·	7	Hugh W. Thompson., "Sterochemical Control of Reductions. The Directive Effect of Carbomethoxy vs. Hydroxymethyl Groups in Catalytic Hydrogenation" The Journal of Organic Chemistry" 1971, pp 2577-2581	
	8	Tyle, P., "Iontophoretic Devices for Drug Delivery." <i>Pharmaceutical Research</i> , Vol. 3, No. 6, 1986, pp. 318-326.	
	9	Venier, Clifford G., et al., "Peroxytrifluoroacetic Acid. A Convenient Reagent for the Preparation of Sulfoxides and Sulfones." <i>J. Or. Chem.</i> , Vol. 47, 1982, pp. 3773-3774.	
	10	Seebach, Dieter, et al., "Herstellung $\alpha$ -thiolierter Carbonylverbindungen." Chem. Ber., Vol. 109, 1976, pp. 1601-1616.	

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.